Michael Forbes, CEO of Adastra, reported in his Preliminary push launch: “Hurt reduction is a critically essential and mainstream topic, and we've been being with the forefront of drug rules throughout the board.” May possibly promote substandard and falsified medications designed or distributed under unregulated and likely unsafe procedures